Scynexis reports Q3 EPS (71c), consensus (72c)
“We are working to advance SCY-770 into a Phase 2 proof-of-concept clinical trial by the end of this year. We believe that our highly selective and direct AMP-activated protein kinase
1w agoSCYX
Compare Stocks
Compare up to 40 stocks
Compared Stocks: 1 / 40
Comparison Results
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SCYX | Healthcare | $3.21 | 64.37K | $33.14M | -2.74 | ― | Moderate Buy |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SCYX | SCYNEXIS | 3.21 | -1.48 | -31.50% |
| Name | Price | % Change | |
|---|---|---|---|
| SCYX | $3.21 | -31.50% |
Custom Stock Latest News
Scynexis files $200M mixed securities shelf08:33 EST Scynexis (SCYX) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on
1w agoSCYX
SCYNEXIS Buy Rating Reaffirmed as Advancing Antifungal Pipeline and BARDA Support Underpin Unchanged $32 Price TargetIn a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on SCYNEXIS, with a price target of $32.00. Jason McCarthy has given his Buy rating due
3w agoSCYX- Scynexis announces topline results from SCY-247 trial
Scynexis (SCYX) announced topline results from its Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, trial of the intravenous, or IV, formulation of SCY-247, its
3w agoSCYX 
SCYNEXIS: Advancing Pipeline and Strong Funding Underpin Buy Rating; $32 Price Target ReaffirmedSCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $32.00
1M agoSCYX
Scynexis completes study of SCY-770Scynexis (SCYX) announced completion of a Phase 1 study of SCY-770, a selective and direct AMP-activated protein kinase activator. The study was conducted to evaluate the safety and tolerability, as
1M agoSCYX
SCYNEXIS Secures BARDA Funding for Antifungal PipelineSCYNEXIS ( ($SCYX) ) just unveiled an update. On September 25, 2026, SCYNEXIS entered into a cost-share contract with the U.S. Biomedical Advanced Research and Development Authority that provides up
Brookline says BARDA contract a major positive for Scynexis’ SCY-247 programBrookline analyst Kemp Dolliver reiterates a Buy rating on Scynexis (SCYX) with a price target of $44 as the firm believes the award of a contract by the Biomedical Advanced
Scynexis awarded contract by BARDA contract, providing up to $214M in fundingScynexis (SCYX) announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, within
1M agoSCYX- SCYNEXIS adds veteran biopharma leader to board
The latest update is out from SCYNEXIS ( ($SCYX) ). On September 18, 2026, SCYNEXIS appointed seasoned biopharmaceutical executive Steven K. Burke, M.D., to its Board of Directors and to
Recent Analysts Ratings of Custom Stocks
Most Recent Earnings of Custom Stocks
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SCYX | Mar 31, 2027TBA | $33.14M | $-0.63 | $158.00K | 0.06 | -2.74 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
- Comprehensive Analysis: Compare up to 40 stocks with detailed metrics including price, market cap, P/E ratio, dividend yield, and more.
- Analyst Ratings: View consensus ratings from top Wall Street analysts and their price targets for each stock.
- Performance Tracking: Analyze historical performance with interactive charts showing 3-month, 6-month, 1-year, YTD, 3-year, and 5-year returns.
- Dividend Information: Evaluate dividend yield, payout ratio, and dividend growth for income-focused investors.
- Earnings Data: Compare earnings per share (EPS), revenue growth, and profitability metrics across companies.
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
All Stock Comparison Categories
Custom Stock - FAQ
Which Custom stocks have a "Strong Buy" analyst rating?
None of the selected stocks have a “Strong Buy” analyst rating consensus.
Are Custom stocks overpriced?
SCYNEXIS's stock price is currently $3.21, and its average 12-month price target is N/A.
Which Custom stocks pay dividends?
SCYNEXIS does not currently pay dividends.